MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Agios Pharmaceuticals Operating Cash Flow 2011-2026 | AGIO
Annual Operating Cash Flow Agios Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -373 M | -390 M | -296 M | -309 M | -407 M | -291 M | -371 M | -304 M | -285 M | 38.6 M | -76.9 M | - | -56.4 M | -49.5 M | -15.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.6 M | -407 M | -228 M |
Quarterly Operating Cash Flow Agios Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -111 M | - | - | - | -99.9 M | - | - | - | -95.2 M | - | -243 M | - | -97.7 M | - | -323 M | - | -121 M | - | -241 M | -173 M | -105 M | - | -277 M | -191 M | -103 M | - | -230 M | -166 M | -99 M | - | -211 M | -133 M | -74.1 M | - | 89.8 M | 139 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.9 M | -26.5 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 139 M | -323 M | -128 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.14 | 0.36 % | $ 443 M |  USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 8.41 | 4.73 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
-42.5 M | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
-607 M | $ 752.35 | 0.79 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 23.83 | 0.85 % | $ 3.03 B | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
BioCardia
BCDA
|
-7.44 M | $ 1.2 | -0.04 % | $ 8 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-52 M | $ 9.6 | 6.37 % | $ 1.98 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-831 M | $ 9.48 | -3.27 % | $ 613 M | USA |
 |
BioVie
BIVI
|
-19 M | $ 1.45 | 2.09 % | $ 2.14 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
828 M | $ 56.49 | 1.78 % | $ 10.8 B | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 92.3 | 1.23 % | $ 27.2 B | Germany |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-39 M | $ 3.04 | 1.54 % | $ 259 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-57.6 M | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.54 | 9.54 % | $ 683 M | Britain |
 |
Cabaletta Bio
CABA
|
-131 M | $ 3.2 | 7.94 % | $ 322 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 3.21 | 4.56 % | $ 6.98 B | Israel |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
1.01 M | $ 19.97 | 2.94 % | $ 1.78 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Codexis
CDXS
|
-19.4 M | $ 1.97 | 7.97 % | $ 172 M | USA |
 |
Cerus Corporation
CERS
|
4.84 M | $ 1.91 | 2.42 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
-176 M | $ 15.4 | 6.72 % | $ 928 M | USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.75 | 0.87 % | $ 205 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |